<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40769446</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3871</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Heart rhythm</Title><ISOAbbreviation>Heart Rhythm</ISOAbbreviation></Journal><ArticleTitle>PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1547-5271(25)02741-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrthm.2025.07.060</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atrial fibrillation (AF) is the most frequent arrhythmia worldwide and a major cause of ischemic stroke. Screening tools are becoming increasingly popular to detect AF for stroke prevention, yet data from randomized trials are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to analyze AF detection rates using a smartphone application with early intervention (intervention group) compared with no intervention (sham group).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is an international, multicenter, prospective, randomized, sham-controlled, double-blinded trial conducted between October 2019 and May 2024. Patients with no prior AF were randomized 1:1 to an intervention group or a sham group. The study application used the smartphone camera to generate photoplethysmography signals. If an arrhythmia was detected, patients in the intervention group received a notification and a 7-day patch electrocardiogram to confirm AF.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1021 patients from 8 centers were randomized. The mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 3.4 &#xb1; 0.92 in the intervention group and 3.5 &#xb1; 1.02 in the sham group. Arrhythmia was detected in 32 (3.1%) cases: 20 (3.9%) in the intervention group and 12 (2.4%) in the sham group. AF was diagnosed in 13 (1.3%) patients. AF detection rates were numerically higher in the intervention group (10 [1.9%] vs 3 [0.5%]; P = .094), especially in cases of asymptomatic AF (4 [0.8%] vs 0 [0%]; P = .13). There was no difference in the rate of stroke, transient ischemic attack, or systemic embolism after 6 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this multicenter trial, application usage in combination with early intervention did not significantly increase overall AF detection rates. However, asymptomatic AF detection was numerically higher in the intervention group, aligning with current guidelines that recommend photoplethysmography-based devices for AF screening.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reichl</LastName><ForeName>Jakob Johannes</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Departement D&amp;ICT, Innovation Management, University Hospital of Basel, Basel, Switzerland; Department of Internal Medicine, University Hospital of Basel, Basel, Switzerland; Department of Cardiology and Cardiovascular Research Institute, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>Khaled Abdel</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departement D&amp;ICT, Innovation Management, University Hospital of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkard</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Cardiovascular Research Institute, University Hospital Basel, Basel, Switzerland; Medical Outpatient Department, University Hospital of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vischer</LastName><ForeName>Annina Salome</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Medical Outpatient Department, University Hospital of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Outpatient Department, University Hospital of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudek</LastName><ForeName>Dariusz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Cardiovascular Interventions University Hospital Jagiellonian University Medical College of Krakow Krakow Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Cardiovascular Interventions University Hospital Jagiellonian University Medical College of Krakow Krakow Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkely</LastName><ForeName>Bela</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe1;szl&#xf3;</LastName><ForeName>Janos Marcell</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manolis</LastName><ForeName>Athanasios J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Cardiology Department, Asklepion Hospital of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallistratos</LastName><ForeName>Manolis S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Cardiology Department, Asklepion Hospital of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linz</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, University Maastricht, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf6;rr</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine B, University Hospital of Greifswald, Greifswald, Germany; Ambulantes Herz-Kreislauf-Zentrum Pasewalk, Pasewalk, Germany; German Centre for Cardiovascular Research, partner site Greifswald, Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahr</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ambulantes Herz-Kreislauf-Zentrum Pasewalk, Pasewalk, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belesin</LastName><ForeName>Branko</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;bner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Preventicus GmbH, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Preventicus GmbH, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piper</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Preventicus GmbH, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckstein</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departement D&amp;ICT, Innovation Management, University Hospital of Basel, Basel, Switzerland; Department of Internal Medicine, University Hospital of Basel, Basel, Switzerland. Electronic address: jens.eckstein@usb.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Rhythm</MedlineTA><NlmUniqueID>101200317</NlmUniqueID><ISSNLinking>1547-5271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AF Screening</Keyword><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Screening</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword><Keyword MajorTopicYN="N">Stroke prevention</Keyword><Keyword MajorTopicYN="N">Wearables</Keyword></KeywordList><CoiStatement>Disclosures Dr H&#xfc;bner is the founder and CEO of Preventicus. Dr K&#xf6;nig and Dr Piper are employees of Preventicus. Dr Eckstein and Dr D&#xf6;rr each holds 0.5% virtual shares of Preventicus. Dr Burkard received grants from the Swiss National Science Foundation, Cardiovascular Research Foundation Basel, AstraZeneca, Daiichi Sankyo, Medtronic, Roche Diagnostics, Novartis, Menarini, Sanofi, Novo Nordisk, and Collabree (outside the submitted work) and lecture and/or travel fees paid to institution by Servier, Medtronic, Sanofi, Novartis, Novo Nordisk, and Daiichi Sankyo (outside the submitted work). Preventicus had no role in the analysis of all data acquired for this study. All other authors confirm that they do not have any conflicts of interest regarding this trial and manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40769446</ArticleId><ArticleId IdType="doi">10.1016/j.hrthm.2025.07.060</ArticleId><ArticleId IdType="pii">S1547-5271(25)02741-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>